Epiomed Therapeutics, Inc., an Irvine, CA-based biopharmaceutical company focused on the discovery and development of novel, small-molecule anti-emetic and anti-motion sickness compounds, has completed its Series A round of financing of undisclosed amount with NDI Capital.
The company intends to use the proceeds from the financing to develop its lead anti-emetic compound, “ETI-0001”, with a Phase 1/2 clinical assessment, which are expected to begin during the first quarter of 2012.
Co-founded by David Helton, Ernest Pfadenhauer and Richard Burgoon and incorporated in October 2010 based upon technology discovered at Cenomed BioSciences, LLC, Epiomed focuses on the discovery, development of novel anti-vomiting and anti-nausea compounds for both the human and veterinary markets.
The company has two pending United States patent applications and one pending international patent application surrounding ETI-0001.
FinSMEs
07/05/2011